Marker Therapeutics Inc. Unveils Presentation on MAR-T Cell Platform and Lead Product MT-601 for Tumor Treatment

Reuters06-05

Marker <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Unveils Presentation on MAR-T Cell Platform and Lead Product MT-601 for Tumor Treatment

Marker Therapeutics Inc. has released a corporate presentation detailing the advancements and strategic positioning of its MAR-T Cell Platform, a non-genetically engineered technology developed at Baylor College of Medicine. The presentation highlights the lead clinical product, MT-601, which targets six tumor-specific antigens and has shown promising results in a Phase 1 clinical trial with a 78% response rate in lymphoma patients. The MAR-T technology is designed for both blood and solid tumors, offering a favorable safety profile without the risk of immune-effector cell associated neurotoxicity syndrome (ICANS). Marker Therapeutics has multiple FDA-cleared INDs for MAR-T based clinical programs and has secured over $30 million in non-dilutive funding. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marker Therapeutics Inc. published the original content used to generate this news brief on June 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2541959030?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-05 03:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541959030","market":"us","top_or_hot":-1,"title":"Marker Therapeutics Inc. Unveils Presentation on MAR-T Cell Platform and Lead Product MT-601 for Tumor Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Marker <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Unveils Presentation on MAR-T Cell Platform and Lead Product MT-601 for Tumor Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Marker Therapeutics Inc. has released a corporate presentation detailing the advancements and strategic positioning of its MAR-T Cell Platform, a non-genetically engineered technology developed at Baylor College of Medicine. The presentation highlights the lead clinical product, MT-601, which targets six tumor-specific antigens and has shown promising results in a Phase 1 clinical trial with a 78% response rate in lymphoma patients. The MAR-T technology is designed for both blood and solid tumors, offering a favorable safety profile without the risk of immune-effector cell associated neurotoxicity syndrome (ICANS). Marker Therapeutics has multiple FDA-cleared INDs for MAR-T based clinical programs and has secured over $30 million in non-dilutive funding. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marker Therapeutics Inc. published the original content used to generate this news brief on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Marker Therapeutics Inc. Unveils Presentation on MAR-T Cell Platform and Lead Product MT-601 for Tumor Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarker Therapeutics Inc. Unveils Presentation on MAR-T Cell Platform and Lead Product MT-601 for Tumor Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-05 03:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Marker <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Unveils Presentation on MAR-T Cell Platform and Lead Product MT-601 for Tumor Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Marker Therapeutics Inc. has released a corporate presentation detailing the advancements and strategic positioning of its MAR-T Cell Platform, a non-genetically engineered technology developed at Baylor College of Medicine. The presentation highlights the lead clinical product, MT-601, which targets six tumor-specific antigens and has shown promising results in a Phase 1 clinical trial with a 78% response rate in lymphoma patients. The MAR-T technology is designed for both blood and solid tumors, offering a favorable safety profile without the risk of immune-effector cell associated neurotoxicity syndrome (ICANS). Marker Therapeutics has multiple FDA-cleared INDs for MAR-T based clinical programs and has secured over $30 million in non-dilutive funding. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marker Therapeutics Inc. published the original content used to generate this news brief on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRKR","symbol_name":"Marker Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDLbk2fLC:1","article_id":"2541959030","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541959030","pubTimestamp":1749063955,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Marker Therapeutics Inc. has released a corporate presentation detailing the advancements and strategic positioning of its MAR-T Cell Platform, a non-genetically engineered technology developed at Baylor College of Medicine. The presentation highlights the lead clinical product, MT-601, which targets six tumor-specific antigens and has shown promising results in a Phase 1 clinical trial with a 78% response rate in lymphoma patients. The MAR-T technology is designed for both blood and solid tumors, offering a favorable safety profile without the risk of immune-effector cell associated neurotoxicity syndrome . Marker Therapeutics has multiple FDA-cleared INDs for MAR-T based clinical programs and has secured over $30 million in non-dilutive funding. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gener","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRKR":"Marker Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Marker Therapeutics Inc.推出用于肿瘤治疗的MAR-T细胞平台和主导产品MT-601","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRKR":0.9},"content_text":"Marker Therapeutics Inc. Unveils Presentation on MAR-T Cell Platform and Lead Product MT-601 for Tumor Treatment\n    \n\n        Marker Therapeutics Inc. has released a corporate presentation detailing the advancements and strategic positioning of its MAR-T Cell Platform, a non-genetically engineered technology developed at Baylor College of Medicine. The presentation highlights the lead clinical product, MT-601, which targets six tumor-specific antigens and has shown promising results in a Phase 1 clinical trial with a 78% response rate in lymphoma patients. The MAR-T technology is designed for both blood and solid tumors, offering a favorable safety profile without the risk of immune-effector cell associated neurotoxicity syndrome (ICANS). Marker Therapeutics has multiple FDA-cleared INDs for MAR-T based clinical programs and has secured over $30 million in non-dilutive funding. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marker Therapeutics Inc. published the original content used to generate this news brief on June 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2541959030","isCrawlerRequest":true}